Corporate Disclosure: Share Acquisition by Fresenius SE & Co. KGaA Managing Board Member

Transaction Overview

On March 20, 2026, Fresenius SE & Co. KGaA (the “Company”) publicly disclosed that one of its managing board members, Sara Hennicken, executed a series of share purchases. The acquisition was structured in four distinct tranches, rather than a single large block, with each tranche executed at a price in the mid‑forties of euros per share (approximately €45–€49). The cumulative volume of the acquisition was nearly 100 000 shares, yielding an aggregate purchase price that also falls within the mid‑forty euro range.

The transactions were cleared on the XETRA exchange (market identifier: XETR). The announcement complied with all applicable regulatory disclosure requirements for director‑dealings under the German Stock Corporation Act (Aktiengesetz) and the European Market Abuse Regulation (EMAR).

Regulatory Context

Under the German market regulation framework, directors are required to report any share transactions that exceed a threshold of €25 000 in a 12‑month period. The Company’s disclosure indicates that the aggregate value of the four tranches exceeded this threshold, thereby triggering the mandatory reporting obligation. The Company has provided all requisite details—date of each transaction, number of shares purchased, price per share, and the cumulative cost—to the German Financial Market Authority (BaFin) and has published the information in the Company’s official disclosure portal and on the XETRA platform.

Implications for Corporate Governance

The disclosed transaction demonstrates the Company’s adherence to transparent corporate governance practices. By reporting the acquisition in a timely manner and providing granular detail on each tranche, the Company mitigates potential concerns about insider trading or undisclosed conflicts of interest. Moreover, the acquisition may be interpreted as an endorsement of the Company’s long‑term prospects by a senior executive, potentially reinforcing investor confidence.

Market Impact Assessment

While the acquisition involves a relatively modest proportion of the Company’s outstanding shares, it could influence short‑term market perception. Analysts may interpret the purchase as a signal of confidence, which could exert upward pressure on share price in the immediate post‑announcement period. Conversely, the lack of accompanying commentary on strategic intentions or future outlook limits the breadth of actionable insight for investors. Market participants should, therefore, weigh this transaction against broader macroeconomic and sectoral trends that currently dominate the healthcare and pharmaceutical markets.

Conclusion

The Director‑deal disclosed on March 20, 2026, reflects standard corporate practice under German and European regulation. The acquisition by Managing Board Member Sara Hennicken is fully compliant, transparently reported, and likely to have a limited direct effect on the Company’s market valuation. Nonetheless, it underscores the importance of timely and detailed disclosure in maintaining robust governance and sustaining stakeholder trust.